2027 ICD-10-CM Diagnosis Code E70.320Tyrosinase negative oculocutaneous albinism
ICD-10-CM Codes›E00–E89›E70-E88›E70
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Chronic Condition
E70.320 is a billable ICD-10-CM diagnosis code for tyrosinase negative oculocutaneous albinism. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 642. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 140 closely related codes. Coders also document this condition as minimal pigment oculocutaneous albinism. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
E70.320 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E70.320 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Minimal pigment oculocutaneous albinism
- Oculocutaneous albinism type 1
- Temperature-sensitive oculocutaneous albinism
- Tyrosinase-negative oculocutaneous albinism
- Yellow mutant oculocutaneous albinism
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to E70.320: its own notes plus those printed at E70.32, block E70-E88, and Chapter 4. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Albinism I
- Oculocutaneous albinism ty-neg
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
- Ehlers-Danlos syndromes (Q79.6-)
Notes
General instructions on how these codes are used.
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name E70.320, its category, or a range that includes it.
Excludes1 4
These codes carry an Excludes1 note naming E70.320: they are not reported together with it, unless the two conditions are unrelated.
- E72 Other disorders of amino-acid metabolismaromatic amino-acid metabolism (E70.-) names E70.-, which includes this code
- R79 Other abnormal findings of blood chemistry
- R79.83 Abnormal findings of blood amino-acid level
- Block R80-R82 Abnormal findings on examination of urine, without diagnosis
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
I E70.320
tyrosinase (ty) negative E70.320
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Albinism, Oculocutaneous
heterogeneous group of autosomal recessive disorders comprising at least four recognized types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. the two most common are the tyrosinase-positive and tyrosinase-negative types.
Patient EducationClinical
Eye Diseases
Even if your eyes feel healthy, you could have a problem and not know it. That's why regular eye exams are so important. Refractive errors are the most common type of vision problem that makes it hard to see clearly. But some eye conditions or diseases don't have any symptoms and can lead to a permanent loss of vision.
The full article covers:
- What diseases can affect the eye?
- What are the symptoms of eye diseases?
- Who is more likely to develop eye diseases?
- What are the treatments for eye diseases?
- Can eye diseases be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E70.320 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E70.320Overview
What is the ICD-10 code for tyrosinase negative oculocutaneous albinism?
The ICD-10-CM code for tyrosinase negative oculocutaneous albinism is E70.320 (sometimes written as E70320). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is E70.320 (Oculocutaneous albinism) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report tyrosinase negative oculocutaneous albinism on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does E70.320 group to?
When tyrosinase negative oculocutaneous albinism is the principal diagnosis on an inpatient stay, it groups to MS-DRG 642 (inborn and Other Disorders of Metabolism), which carries a relative weight of 1.3226. Higher weights mean higher Medicare reimbursement.
Is E70.320 a CC or MCC?
CMS lists E70.320 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 140 closely related codes in its exclusion list.
Can E70.320 be reported with E70.330?
Not as a rule. The Excludes1 note at E70.32, which applies to E70.320, lists "Chediak-Higashi syndrome (E70.330)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does E70.320 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage. E70.320 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).
